Coagulation factors are protein components of the blood which serve blood coagulation.
Search results 26 to 50 from a total of 87
| Name | Marketing Authorisation Holder | License Number | License Date | Further Information |
|---|---|---|---|---|
|
Haemocomplettan P 1g |
CSL Behring GmbH |
PEI.H.03265.01.1 | 22.03.2005 | Rote-Hand-Brief: Haemocomplettan und Riastap (01.04.2019) |
|
Fibrogammin 1250 |
CLS Behring GmbH |
PEI.H.03242.02.1 | 07.02.2005 | |
|
Fibrogammin 250 |
CSL Behring GmbH |
PEI.H.03242.01.1 | 07.02.2005 | |
|
Octaplex 1000 |
OCTAPHARMA GmbH |
PEI.H.02312.02.1 | 11.08.2015 | |
|
OCTAPLEX 500 |
OCTAPHARMA GmbH |
PEI.H.02312.01.1 | 14.03.2003 | |
|
Wilate 1000 |
OCTAPHARMA GmbH |
PEI.H.01918.04.1 | 22.12.2011 | |
|
Wilate 500 |
OCTAPHARMA GmbH |
PEI.H.01918.03.1 | 22.12.2011 | |
|
Wilate 900 |
OCTAPHARMA GmbH |
PEI.H.01918.02.1 | 08.02.2005 | |
|
Wilate 450 |
OCTAPHARMA GmbH |
PEI.H.01918.01.1 | 08.02.2005 | |
ReFacto AF |
Pfizer Europe MA EEIG |
EU/1/99/103 | 13.04.1999 | |
BeneFIX |
Pfizer Europe MA EEIG |
EU/1/97/047 | 27.08.1997 | |
|
NovoSeven |
Novo Nordisk A/S |
EU/1/96/006 | 23.02.1996 | |
Altuvoct |
Swedish Orphan Biovitrum AB, Schweden |
EU/1/24/1824 | 17.06.2024 | |
Cevenfacta |
Laboratoire francais du Fractionement et des Biotechnologies, Frankreich |
EU/1/22/1664 | 15.07.2022 | |
Esperoct |
Novo Nordisk A/S, Dänemark |
EU/1/19/1374 | 20.06.2019 | |
Jivi |
Bayer AG |
EU/1/18/1324 | 22.11.2018 | |
|
Veyvondi |
Baxalta Innovations GmbH |
EU/1/18/1298 | 31.08.2018 | |
|
Adynovi |
Baxalta Innovations GmbH, A |
EU/1/17/1247 | 08.01.2018 | |
|
Refixia |
Novo Nordisk A/S, Denmark |
EU/1/17/1193 | 02.06.2017 | |
|
Vihuma |
Octapharma AB, Stockholm |
EU/1/16/1168 | 13.02.2017 | |
|
Afstyla |
CSL Behring GmbH |
EU/1/16/1158 | 04.01.2017 | |
|
Alprolix |
Swedish Orphan Biovitrum AB (publ) |
EU/1/16/1098 | 12.05.2016 | |
|
Idelvion |
CSL Behring GmbH |
EU/1/16/1095 | 11.05.2016 | |
|
Coagadex |
Bio Products Laboratory Ltd., UK-Hertfordshire |
EU/1/16/1087 | 16.03.2016 | |
|
Kovaltry |
Bayer AG |
EU/1/15/1076 | 18.02.2016 |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 529 in BAnz AT 30.05.2025 B6.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 02.06.2025
